« Back
Home /
Momelotinib

Momelotinib

Item no.	HY-10961-1mg
Manufacturer	MedChem Express
CASRN	1056634-68-4
Amount	1 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 mg 200 mg 50 mg 5 mg
Category	Oncology Metabolism Diabetes Glucose Homeostasis Inhibitors & Compound Libraries Small Molecules By Organ Heart & Blood Cancer Lymphatic System Cancer
Type	Inhibitors
Specific against	other
Purity	99.37
Citations	[1]Pardanani A, et al. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia, 2009, 23(8), 1441-1445.\|[2]Monaghan KA, et al. The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells. Leukemia, 2011, 25(12), 1891-1899.\|[3]Tyner JW, et al. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood, 2010, 115(25), 5232-5240.\|[4]Kitajima S, et al.Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRAS.Cancer Cell. 2018 Sep 10;34(3):439-452.e6. BANGL J PHARMACOL. 2023 Dec 17.\|Cancer Cell. 2018 Sep 10;34(3):439-452.e6. \|Cancer Immunol Res. 2016 Jun;4(6):520-30.\|Cancer Res. 2020 Jan 1;80(1):44-56. \|Cell Death Dis. 2022 Dec 27;13(12):1075.\|Cell Syst. 2018 Apr 25;6(4):424-443.e7.\|Harvard Medical School LINCS LIBRARY\|Immunol Invest. 2021 Oct 27;1-16.\|Int J Biol Sci. 2022 Jan 1;18(2):585-598.\|Int J Biol Sci. 2022; 18(2): 585-598.\|J Pineal Res. 2019 Apr;66(3):e12552.\|Leukemia. 2012 Oct;26(10):2233-44.\|Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.\|Harvard Medical School LINCS LIBRARY
Smiles	O=C(C1=CC=C(C2=NC(NC3=CC=C(N4CCOCC4)C=C3)=NC=C2)C=C1)NCC#N
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	CYT387
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	Apoptosis; Autophagy; JAK
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	414.46
Product Description	Momelotinib (CYT387) is an ATP-competitive inhibitor of JAK1/JAK2 with IC50a of 11 nM and 18 nM, respectively. CYT387 shows much less activity against JAK3.
Manufacturer - Research Area	Cancer
Solubility	DMSO: 10 mg/mL (ultrasonic; warming; adjust pH to 3 with HCl; heat to 60°C)
Manufacturer - Pathway	Apoptosis; Autophagy; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Isoform	JAK1; JAK2; JAK3
Clinical information	Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-10961-1mg-safety-datasheet.pdf